News AstraZeneca PLC

Equities

AZN

GB0009895292

Market Closed - London S.E. Other stock markets 11:35:29 2024-04-17 am EDT			5-day change	1st Jan Change
10,862 ^GBX	-0.15%		+1.21%	+2.47%

Apr. 17	AstraZeneca: presents new data at ECCMID	CF
Apr. 17	The market is pinning its hopes on earnings reports

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials	Apr. 17	AQ
AstraZeneca: presents new data at ECCMID	Apr. 17	CF
The market is pinning its hopes on earnings reports	Apr. 17
ASTRAZENECA : Receives a Buy rating from JP Morgan	Apr. 17	ZD
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid Growing Radiopharma Interest	Apr. 17	AQ
ANALYST RECOMMENDATIONS : Las Vegas Sands, Regeneron, Kinder Morgan, Rivian, Royal Caribbean...	Apr. 17
Market sentiment sours	Apr. 16
ASTRAZENECA : Deutsche Bank returns to 'Hold	Apr. 16	CF
Deutsche Bank Upgrades AstraZeneca to Hold from Sell, Lifts PT	Apr. 16	MT
Astrazeneca - New modelling reveals the escalating toll of chronic kidney disease on patients, planet and economies	Apr. 16	AQ
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial	Apr. 16	BU
Astrazeneca plc Announces IMFINZI Plus Chemotherapy Doubled Overall Survival Rate At Three Years for Patients with Advanced Biliary Tract Cancer in Topaz-1 Phase III Trial	Apr. 16	CI
ASTRAZENECA : Deutsche Bank drops its Sell rating	Apr. 16	ZD
ANALYST RECOMMENDATIONS : AMD, Colgate, Fair Isaac, Tyson Foods, AstraZeneca	Apr. 16
RBC raises Admiral; Barclays cuts Phoenix Group	Apr. 16	AN
AstraZeneca: improvements in biliary tract cancer	Apr. 16	CF
AstraZeneca's hails Imfinzi survival data on cancer form	Apr. 16	AN
AstraZeneca's Biliary Tract Cancer Combo Improves Overall Survival in Late-stage Trial	Apr. 16	MT
Asher Biotherapeutics, Inc. announced that it has received $55 million in funding from a group of investors	Apr. 15	CI
AstraZeneca: expects a sharp rise in kidney disease	Apr. 15	CF

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ASTRAZENECA : AstraZeneca should not be overlooked for long

April 03, 2024 at 10:26 am EDT